Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics for inflammatory and immune-related diseases, has announced its participation in the upcoming Leerink Partners Therapeutics Forum. The company's CEO, Dr. Taylor Schreiber, will participate in a panel discussion focused on DR3/TL1A and IBD on July 8, 2025.
The presentation, titled "TL1A: Pioneering a New MOA in IBD and Beyond," will take place at 4:15-5:00 PM ET at the Boston Harbor Hotel. Management will also be available for one-on-one meetings during the conference on July 8-9, 2025.
Shattuck Labs (NASDAQ: STTK), un'azienda biotecnologica specializzata nello sviluppo di nuovi trattamenti per malattie infiammatorie e immunitarie, ha annunciato la sua partecipazione al prossimo Leerink Partners Therapeutics Forum. Il CEO dell'azienda, Dr. Taylor Schreiber, prender脿 parte a una tavola rotonda dedicata a DR3/TL1A e alle malattie infiammatorie intestinali (IBD) il 8 luglio 2025.
La presentazione, intitolata "TL1A: Pionieri di un nuovo meccanismo d'azione nelle IBD e oltre", si terr脿 dalle 16:15 alle 17:00 ET presso il Boston Harbor Hotel. Il management sar脿 inoltre disponibile per incontri individuali durante la conferenza, dal 8 al 9 luglio 2025.
Shattuck Labs (NASDAQ: STTK), una empresa biotecnol贸gica enfocada en desarrollar nuevos tratamientos para enfermedades inflamatorias y relacionadas con el sistema inmunol贸gico, ha anunciado su participaci贸n en el pr贸ximo Leerink Partners Therapeutics Forum. El CEO de la compa帽铆a, Dr. Taylor Schreiber, participar谩 en un panel de discusi贸n centrado en DR3/TL1A y EII el 8 de julio de 2025.
La presentaci贸n, titulada "TL1A: Pioneros en un nuevo mecanismo de acci贸n en EII y m谩s all谩", se realizar谩 de 4:15 a 5:00 PM ET en el Boston Harbor Hotel. La direcci贸n tambi茅n estar谩 disponible para reuniones individuales durante la conferencia del 8 al 9 de julio de 2025.
Shattuck Labs (NASDAQ: STTK)電� 鞐检 氚� 氅挫棴 甏�霠� 歆堩櫂鞐� 雽�頃� 靸堧鞖� 旃橂氩� 臧滊皽鞐� 欤茧牓頃橂姅 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 雼り岸撵槫電� Leerink Partners Therapeutics Forum鞐� 彀胳棳頃� 瓴冹瀯鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� CEO鞚� Dr. Taylor Schreiber臧赌 2025雲� 7鞗� 8鞚� DR3/TL1A 氚� 鞐检靹� 鞛レ頇�(IBD)鞚� 欤检牅搿� 頃� 韺剱 韱犽鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
"TL1A: IBD 氚� 攴� 鞚挫儊鞚� 靸堧鞖� 鞛戩毄旮办爠 臧滌矙"鞚措澕電� 鞝滊鞚� 氚滍憸電� 霃欕秬鞁滉皠 旮办 鞓ろ泟 4鞁� 15攵勲秬韯� 5鞁滉箤歆� 氤挫姢韯� 頃橂矂 順疙厰鞐愳劀 歆勴枆霅╇媹雼�. 瓴届榿歆勳潃 2025雲� 7鞗� 8鞚茧秬韯� 9鞚缄箤歆� 鞐措Μ電� 旎嵓霟办姢 旮瓣皠 霃欖晥 1:1 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
Shattuck Labs (NASDAQ : STTK), une entreprise biotechnologique sp茅cialis茅e dans le d茅veloppement de nouveaux traitements pour les maladies inflammatoires et immunitaires, a annonc茅 sa participation au prochain Leerink Partners Therapeutics Forum. Le PDG de la soci茅t茅, Dr. Taylor Schreiber, participera 脿 une table ronde ax茅e sur DR3/TL1A et les maladies inflammatoires de l'intestin (MII) le 8 juillet 2025.
La pr茅sentation, intitul茅e "TL1A : Pionnier d鈥檜n nouveau m茅canisme d鈥檃ction dans les MII et au-del脿", aura lieu de 16h15 脿 17h00 ET 脿 l鈥檋么tel Boston Harbor. La direction sera 茅galement disponible pour des r茅unions individuelles pendant la conf茅rence les 8 et 9 juillet 2025.
Shattuck Labs (NASDAQ: STTK), ein Biotechnologieunternehmen, das sich auf die Entwicklung neuartiger Therapeutika f眉r entz眉ndliche und immunbedingte Erkrankungen spezialisiert hat, hat seine Teilnahme am bevorstehenden Leerink Partners Therapeutics Forum angek眉ndigt. Der CEO des Unternehmens, Dr. Taylor Schreiber, wird an einer Podiumsdiskussion zum Thema DR3/TL1A und entz眉ndliche Darmerkrankungen (IBD) am 8. Juli 2025 teilnehmen.
Die Pr盲sentation mit dem Titel "TL1A: Wegweisend f眉r einen neuen Wirkmechanismus bei IBD und dar眉ber hinaus" findet von 16:15 bis 17:00 Uhr ET im Boston Harbor Hotel statt. Das Management steht au脽erdem f眉r Einzelgespr盲che w盲hrend der Konferenz am 8. und 9. Juli 2025 zur Verf眉gung.
- None.
- None.
AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8鈥�9, 2025 in Boston, MA.
Conference Details
Format: Panel Discussion and one-on-one meetings
Session Title: TL1A: Pioneering a New MOA in IBD and Beyond
Moderators: Thomas J. Smith, Analyst, Leerink & Faisal A. Khurshid, Analyst, Leerink
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck鈥檚 Chief Executive Officer
Date: July 8, 2025
Time: 4:15-5:00 PM ET
Location: Boston Harbor Hotel, Boston, MA
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck鈥檚 preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 has completed a GLP toxicology study in non-human primates, with an IND filing expected in the third quarter of 2025.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck鈥檚 expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
FAQ
When is Shattuck Labs (STTK) presenting at the Leerink Partners Therapeutics Forum 2025?
Who will be presenting for Shattuck Labs at the Leerink Partners conference?
What is the topic of Shattuck Labs' panel discussion at the Leerink Partners conference?
Where can investors meet with Shattuck Labs management during the Leerink conference?
